Oracle stock price has suffered a major reversal as concerns about the artificial intelligence (AI) and its soaring debt remain. ORCL dropped to a low of $198, down by over 36% from its highest point this year. Its market cap has dropped from over $967 billion to $530 billion. 

Oracle stock has crashed amid debt concerns

One of the main reasons why the ORCL stock price has plunged is that investors are concerns about its soaring debt. It recently raised $18 billion in debt, bringing its combined borrowings to over $100 billion. 

The company intends to use these fund to fund its large data center operations. These funds are likely part of the Stargate project that also includes OpenAI and Softbank.

However, investors are betting against its stock and debt amid the rising concerns about the potential AI bubble. 

Data compiled by Bloomberg shows that the price to protect against the company defaulting on it debt has jumped to 1.11 percentage points. This is equivalent to about $111,000 for every $10 million.

More data shows that the company’s CDS has jumped to about $5 billion from $200 million in the same period last year. 

Concerns about the AI industry remains

Oracle stock price has also dropped because of the rising concerns about the AI industry, which some investors believe is in a bubble. Indeed, some notable investors like Masayoshi Son, Peter Thiel, and Michael Burry have dumped their Nvidia shares. 

Also, while many AI companies have jumped this year, most of them have pulled back from their YTD highs. Palantir stock has plunged by 25% from the year-to-date high. Other companies like CoreWeave, Nebius, and IREN have also tumbled in the past few weeks.

One of the main concerns about this is the web of deals that Oracle has entered in the past few months. One of this deals is its partnership with OpenAI that will see it receive $30 billion a year for data center services. 

The main concern is that OpenAI does not have that money as it is expected to make between $12.7 billion and $20 billion this year. Also, OpenAI has made deals worth over $1 trillion with companies like Broadcom, CoreWeave, Nvidia, and AMD. 

The most recent results showed that the company’s remaining performance obligations (RPO) jumped by 359% in its first quarter to $455 billion. Its revenue rose by 12% to $14.9 billion, while its EPS dropped by 2% to $1.01. 

Oracle share price technical analysis

The daily timeframe chart shows that the ORCL stock price peaked at $345 and then plunged to the current $200. It has dived to the lowest level since June. 

The stock has moved below the 61.8% Fibonacci Retracement level. It has also moved below the 50-day and 200-day Exponential Moving Averages (EMA). Dropping below these averages is a sign that bears are in control. 

Oracle stock has moved below the Supertrend and the Ichimoku cloud indicators. Therefore, the most likely scenario is whre it continues falling, potentially to the 78.6% retracement level and then it starts to climb as investors buy the dip.

The post Oracle stock price comes back to earth: is ORCL a buy now? appeared first on Invezz

Eli Lilly crossed into historic territory on Friday, becoming the first healthcare company ever to hit a $1 trillion market valuation.

Shares rose 1.7% to mark the milestone, cementing the Indianapolis pharmaceutical giant as Wall Street’s newest mega-cap champion.

With stock gains exceeding 36% year-to-date, Lilly has dramatically outpaced tech volatility and signaled a major investor rotation toward defensive, high-growth healthcare plays, especially as mega-cap tech faces mounting questions about valuations and returns.

The GLP-1 goldmine: How obesity drugs minted a trillion-dollar giant

Lilly’s ascent rests almost entirely on two blockbuster drugs: Mounjaro, which treats type 2 diabetes, and Zepbound, the weight-loss injection.

Together, they’re rewriting pharmaceutical economics. In Q3 2025, the duo generated $10.1 billion in combined revenue, more than 57% of Lilly’s total $17.6 billion quarterly sales.

Mounjaro nearly doubled to $6.52 billion, crushing analyst expectations of $5.51 billion, while Zepbound nearly tripled to $3.57 billion, topping estimates of $3.5 billion.​

The commanding market share tells the real story. Lilly now captures nearly 60% of all US GLP-1 prescriptions, compared to competitor Novo Nordisk, which commands just 42%.

This dominance reflects both superior drug efficacy; Mounjaro’s dual-action mechanism outperforms Novo’s single-target semaglutide and Lilly’s aggressive direct-to-consumer strategy.

The Walmart partnership to sell Zepbound vials at lower cash prices has particularly resonated with price-sensitive patients.​

Wall Street projects breathtaking growth ahead.

Analysts estimate the weight-loss drug market could reach $150 billion by the early 2030s, with Truist Securities predicting Lilly’s obesity portfolio, including the upcoming oral drug orforglipron, due early 2026, could hit $101 billion in peak worldwide revenue.

A White House pricing deal on GLP-1s could unlock another 40 million Medicare patients, dramatically expanding the addressable market size.

Once considered niche, obesity treatment has become the most profitable healthcare category.​

Beyond obesity: Why Lilly is the ‘new magnificent seven’ for risk-averse investors

Lilly’s trillion-dollar valuation signals a fundamental shift in investor sentiment.

With mega-cap technology stocks under pressure over AI capex returns, Lilly offers what tech cannot: predictable, near-term revenue growth tied to an expanding addressable market.

The company trades at roughly 51x forward earnings, a premium, yes, but justified by recurring growth less vulnerable to semiconductor cycles or geopolitical whipsaw.​

CEO Dave Ricks is deliberately positioning Lilly as a long-term compounder.

His strategy includes an R&D partnership with Nvidia, launching a drug-discovery supercomputer in January 2026, signaling intent to extend innovation pipelines beyond the patent cliff.

The risks remain real: pricing pressures on Mounjaro and execution risks on orforglipron could test momentum.

But for now, Lilly has captured the market imagination as the anti-tech mega-cap story, rare validation for healthcare in a tech-dominated era.

The post Wall Street’s new darling: Eli Lilly becomes healthcare’s first $1 trillion powerhouse appeared first on Invezz

Palo Alto Networks Inc (NASDAQ: PANW) came in ahead of Street estimates in its fiscal Q1 and issued slightly better-than-expected guidance for the full year as well on Thursday.

Still, the cybersecurity stock opened in the red this morning as two underlying weaknesses in the company’s earnings release eclipsed its strong headline number.

Versus its October high, Palo Alto Networks’ stock is now down more than 10%.

Profitability concerns are hurting Palo Alto Networks’ stock

PANW posted impressive growth in revenue for its fiscal Q1, but its bottom-line performance told a different story altogether.

The Nasdaq-listed firm saw its net income slip 5% year-on-year to $334 million in the first quarter, signaling rising costs or margin pressure.

For a company in the midst of aggressive expansion, shrinking net income can signal inefficiencies or dilution of earnings power. Investors often reward growth stories when profitability scales in tandem.

In Palo Alto Networks’ case, the earnings contraction may have triggered skepticism about whether its acquisition-heavy strategy is sustainable.

A post-earnings decline in PANW shares reflects this broader shift toward rewarding operational discipline over pure growth.

PANW shares are slipping due to rising capital expenditures

In Q1, Palo Alto Networks’ capital expenditures (CAPEX) climbed to $84 million – well over $58 million that analysts had forecast.

That’s a 44% overshoot – at a time when investors are increasingly wary of aggressive spending. Across tech, elevated capex has become a major red flag – especially when paired with declining net income.

PANW’s spending spree includes its $3.35 billion bid for Chronosphere and a pending $25 billion acquisition of CyberArk.

While these moves may strengthen its artificial intelligence (AI) and identity security capabilities, the near-term optics sure are challenging.

Investors are asking: Is the company overextending itself? The capex concerns are adding fuel to the fire – making investors bail on Palo Alto Networks shares today – even as management touts long-term strategic value.

Should you buy the dip? Cramer thinks so

Despite the post-earnings sell-off, some market veterans remain constructive on PANW stock. Jim Cramer, speaking to CNBC’s Investing Club, reaffirmed his confidence in Palo Alto’s long-term trajectory.

Given the endless hacks lately from the Chinese using really sophisticated equipment, I think there’s plenty of business for these guys.

The former hedge fund manager expressed confidence in Nikesh Aurora’s leadership and praised the company’s CyberArk acquisition, calling it “just sensational.”

He noted that Palo Alto Networks’ stock hasn’t fallen much from its highs compared to other tech names – emphasizing the enduring demand for cybersecurity solutions.

For long-term investors, this dip may be more opportunity than warning, Cramer concluded. Wall Street also currently has an “overweight” rating on the cybersecurity stock with an average target of about $226, indicating potential upside of 15% from here.

The post Why is Palo Alto Networks stock sinking despite solid earnings, upbeat guidance? appeared first on Invezz

Dycom Industries stock (NYSE: DY) surged nearly 18% Wednesday following strong third-quarter results that crushed analyst expectations and sparked a major upward revision to fiscal 2026 guidance.

The telecommunications and utility services contractor reported record revenue of $1.452 billion and diluted earnings of $3.63 per share, beating Street estimates by 13% on profit.

The company also raised its full-year revenue outlook midpoint, signaling robust demand for digital infrastructure despite broader economic uncertainty.

CEO Dan Peyovich called it “an exceptional quarter” that “reinforced industry leadership,” setting the tone for what could be a significant inflection point for the stock.​

Dycom’s dramatic 18% rally reflects investor relief and enthusiasm over three converging factors: beat earnings, record backlog, and raised guidance.

The stock had already climbed steadily through the the fall, but today’s move caps a remarkable 109% gain since November 2024 lows.

At current levels, Dycom now trades at an $8.6 billion market cap, a reflection of how quickly market sentiment shifted once investors recognized the durability of the company’s growth engine.​

Why did Dycom Industries’ stock skyrocket today?

The earnings surprise was substantial across multiple metrics. Q3 contract revenues climbed 14.1% year-over-year to $1.452 billion, while GAAP diluted EPS jumped 35.4% to $3.63 versus consensus expectations of $3.20.

Net income expanded 34.4% to $106.4 million, and adjusted EBITDA surged 28.5% to $219.4 million with a margin of 15.1%, up 170 basis points from the prior year quarter.​

But the real eye-popper was the the backlog. Dycom reported a record $8.2 billion in backlog as of October 25, 2025, providing extraordinary visibility into future revenue.

For context, this represents roughly 1.5 years of revenue at current run rates, a fortress of work already committed.

The backlog expansion underscores just how desperate customers are for Dycom’s expertise in in deploying broadband and 5G infrastructure across America.​

Management also raised the midpoint of fiscal 2026 revenue guidance to a range of $5.350 billion–$5.425 billion, implying growth of 13.8% to 15.4%.

Q4 guidance of $1.26–$1.34 billion in revenue came in line with Street expectations.

Notably, management attributed growth to “significantly higher customer demand for digital infrastructure” and execution on recent acquisitions, particularly the Black and Veatch purchase announced earlier this year.​

What analysts are saying

The reaction from Wall Street has been swift and positive.

Wells Fargo maintained an “overweight” rating and raised its price target to $315, implying 1.6% upside from current levels.

DA Davidson, Raymond James, and JPMorgan have all raised their price targets following the earnings beat, with consensus now sitting at $302.63.​

Analysts point to three structural tailwinds supporting Dycom’s trajectory. First, broadband infrastructure spending remains elevated.

The Broadband, Equity, Access and Deployment (BEAD) program, funded through the Infrastructure Investment and Jobs Act, has already begun deployment, with Dycom positioned as a primary beneficiary.

Second, private investment in 5G densification and fiber buildout continues accelerating as carriers upgrade networks.

Third, M&A synergies from the Black and Veatch acquisition are beginning to translate into higher margins; the adjusted EBITDA margin of 15.1% in Q3 marks meaningful expansion from prior periods.​

One concern flagged by some analysts is labor availability in a tight market.

Dycom guided to 3.8%–5.1% growth contingent on workforce scalability, suggesting management sees labor as the potential constraint rather than demand.

However, the company’s track record of of managing rapid scaling (22% growth two years ago) suggests this is manageable rather than existential.​

At $310, Dycom now trades at 33x forward earnings, a notable premium to its historical average but justified by the combination of record backlog, margin expansion, and a multi-year runway of BEAD-funded infrastructure deployment.​

The post Why is Dycom Industries stock soaring 18% today: here’s what analysts say appeared first on Invezz